Articles by Alan S. Go, MD

Anticoagulation in Atrial Fibrillation: Impact of Mental Illness
BySusan K. Schmitt, PhD,Mintu P. Turakhia, MD, MAS,Ciaran S. Phibbs, PhD,Rudolf H. Moos, PhD,Dan Berlowitz, MD, MPH,Paul Heidenreich, MD, MS,Victor Y. Chiu, MD,Alan S. Go, MD,Sarah A. Friedman, MSPH,Claire T. Than, MPH,Susan M. Frayne, MD, MPH Atrial fibrillation patients with mental health conditions are less likely to be eligible for warfarin receipt, and those who are eligible receive warfarin at lower rates.

Ethnic Differences in the Development of Albuminuria: The DISTANCE Study
ByAndy I. Choi, MD, MAS,Andrew J. Karter, PhD,Jennifer Y. Liu, MPH,Bessie A. Young, MD, MPH,Alan S. Go, MD,Dean Schillinger, MD Despite uniform access to medical care, Filipinos, blacks, and Asians with diabetes developed albuminuria at higher rates than whites.

Mental Illness and Warfarin Use in Atrial Fibrillation
ByGraham A. Walker, MD,Paul A. Heidenreich, MD, MS,Ciaran S. Phibbs, PhD,Alan S. Go, MD,Victor Y. Chiu, BA,Susan K. Schmitt, PhD,Lakshmi Ananth, MS,Susan M. Frayne, MD, MPH Atrial fibrillation patients with mental illness are less likely to receive warfarin anticoagulation; those who do receive warfarin have excess risk of over-anticoagulation.

Glycemic Response to Newly Initiated Diabetes Therapies
ByAndrew J. Karter, PhD,Howard H. Moffet, MPH,Jennifer Liu, MPH,Melissa M. Parker, MS,Ameena T. Ahmed, MD,Alan S. Go, MD,Joe V. Selby, MD 